Santiago Arroyo Biography and Net Worth

Insider of Bicycle Therapeutics

Santiago Arroyo, M.D., Ph.D. is the chief development officer of Bicycle Therapeutics.

Santiago was most recently the Chief Medical Officer of Fulcrum Therapeutics. Previously, he was Chief Medical Officer of Momenta Pharmaceuticals culminating in the acquisition by Johnson & Johnson for $6.5 billion in 2020. As Chief Medical Officer at Momenta, he led the clinical development of the company’s portfolio of hematology, neurology, immunology, and materno-fetal therapeutics. Previously, he was the Chief Medical Officer of Boston Pharmaceuticals and before that held multiple senior clinical development leadership roles at leading pharmaceutical companies. Santiago served as Senior Vice President, Head of Clinical Research and Chief Medical Officer of Pharmatherapeutics at Pfizer, Inc. and was therapeutic area head for neurosciences, discovery medicine and clinical pharmacology at Bristol-Myers Squibb. Earlier, he held clinical development roles at Eisai Global Clinical Development and Schwarz Biosciences.

Santiago was an Instructor at the Johns Hopkins Medical School, Associate Professor at the Medical College of Wisconsin and Senior Specialist at the Hospital Clinic of Barcelona. He earned a Ph.D. from the Universidad de Barcelona and an M.D. from the Universidad Autonóma de Madrid. Finally, he a non-executive director of Lundbeck and GlycoEra AG.

What is Santiago Arroyo's net worth?: The estimated net worth of Santiago Arroyo is at least $493.07 thousand as of January 2nd, 2025. Arroyo owns 69,057 shares of Bicycle Therapeutics stock worth more than $493,067 as of December 4th. This net worth evaluation does not reflect any other assets that Arroyo may own. Additionally, Arroyo receives a salary of $916,980.00 as Insider at Bicycle Therapeutics. Learn More about Santiago Arroyo's net worth.
How old is Santiago Arroyo?: Arroyo is currently 64 years old. There are 6 older executives and no younger executives at Bicycle Therapeutics. The oldest executive at Bicycle Therapeutics is Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director, who is 73 years old. Learn More on Santiago Arroyo's age.
What is Santiago Arroyo's salary?: As the Insider of Bicycle Therapeutics PLC Sponsored ADR, Arroyo earns $916,980.00 per year. The highest earning executive at Bicycle Therapeutics is Dr. Kevin Lee M.B.A., Ph.D., CEO & Executive Director, who commands a salary of $1,350,000.00 per year. Learn More on Santiago Arroyo's salary.
How do I contact Santiago Arroyo?: The corporate mailing address for Arroyo and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Santiago Arroyo's contact information.
Has Santiago Arroyo been buying or selling shares of Bicycle Therapeutics?: Santiago Arroyo has not been actively trading shares of Bicycle Therapeutics during the last ninety days. Most recently, Santiago Arroyo sold 4,943 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a transaction totalling $69,646.87. Following the completion of the sale, the insider now directly owns 69,057 shares of the company's stock, valued at $973,013.13. Learn More on Santiago Arroyo's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Santiago Arroyo (Insider), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), Pierre Legault (Director), Alistair Milnes (COO), Michael Skynner (CTO), Travis Thompson (CAO), and Alethia Young (CFO). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, Bicycle Therapeutics insiders bought shares 2 times. They purchased a total of 1,485,397 shares worth more than $21,229,062.72. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 49,366 shares worth more than $563,681.34. The most recent insider tranaction occured on October, 3rd when CEO Kevin Lee sold 3,231 shares worth more than $27,172.71. Insiders at Bicycle Therapeutics own 22.9% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 10/3/2025.

Santiago Arroyo Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/2/2025	Sell	4,943	$14.09	$69,646.87	69,057

Santiago Arroyo Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $7.14

$6.96

$7.27

50 Day Range

MA: $7.48

$6.17

$8.87

2 Week Range

Now: $7.14

$6.03

$21.50

Volume

302,559 shs

Average Volume

327,116 shs

Market Capitalization

$495.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Santiago Arroyo Biography and Net Worth

What is Santiago Arroyo's net worth?

How old is Santiago Arroyo?

What is Santiago Arroyo's salary?

How do I contact Santiago Arroyo?

Has Santiago Arroyo been buying or selling shares of Bicycle Therapeutics?

Who are Bicycle Therapeutics' active insiders?

Are insiders buying or selling shares of Bicycle Therapeutics?